ATR 10-Q Quarterly Report March 31, 2013

APTARGROUP INC

10-Qs and 10-Ks

10-Q	Quarter ended March 31, 2025
10-K	Fiscal year ended Dec. 31, 2024
10-Q	Quarter ended Sept. 30, 2024
10-Q	Quarter ended June 30, 2024
10-Q	Quarter ended March 31, 2024
10-K	Fiscal year ended Dec. 31, 2023
10-Q	Quarter ended Sept. 30, 2023
10-Q	Quarter ended June 30, 2023
10-Q	Quarter ended March 31, 2023
10-K	Fiscal year ended Dec. 31, 2022
10-Q	Quarter ended Sept. 30, 2022
10-Q	Quarter ended June 30, 2022
10-Q	Quarter ended March 31, 2022
10-K	Fiscal year ended Dec. 31, 2021
10-Q	Quarter ended Sept. 30, 2021
10-Q	Quarter ended June 30, 2021
10-Q	Quarter ended March 31, 2021
10-K	Fiscal year ended Dec. 31, 2020
10-Q	Quarter ended Sept. 30, 2020
10-Q	Quarter ended June 30, 2020
10-Q	Quarter ended March 31, 2020
10-K	Fiscal year ended Dec. 31, 2019
10-Q	Quarter ended Sept. 30, 2019
10-Q	Quarter ended June 30, 2019
10-Q	Quarter ended March 31, 2019
10-K	Fiscal year ended Dec. 31, 2018
10-Q	Quarter ended Sept. 30, 2018
10-Q	Quarter ended June 30, 2018
10-Q	Quarter ended March 31, 2018
10-K	Fiscal year ended Dec. 31, 2017
10-Q	Quarter ended Sept. 30, 2017
10-Q	Quarter ended June 30, 2017
10-Q	Quarter ended March 31, 2017
10-K	Fiscal year ended Dec. 31, 2016
10-Q	Quarter ended Sept. 30, 2016
10-Q	Quarter ended June 30, 2016
10-Q	Quarter ended March 31, 2016
10-K	Fiscal year ended Dec. 31, 2015
10-Q	Quarter ended Sept. 30, 2015
10-Q	Quarter ended June 30, 2015
10-Q	Quarter ended March 31, 2015
10-K	Fiscal year ended Dec. 31, 2014
10-Q	Quarter ended Sept. 30, 2014
10-Q	Quarter ended June 30, 2014
10-Q	Quarter ended March 31, 2014
10-K	Fiscal year ended Dec. 31, 2013
10-Q	Quarter ended Sept. 30, 2013
10-Q	Quarter ended June 30, 2013
10-Q	Quarter ended March 31, 2013
10-K	Fiscal year ended Dec. 31, 2012
10-Q	Quarter ended Sept. 30, 2012
10-Q	Quarter ended June 30, 2012
10-Q	Quarter ended March 31, 2012
10-K	Fiscal year ended Dec. 31, 2011
10-Q	Quarter ended Sept. 30, 2011
10-Q	Quarter ended June 30, 2011
10-Q	Quarter ended March 31, 2011
10-K	Fiscal year ended Dec. 31, 2010
10-Q	Quarter ended Sept. 30, 2010
10-Q	Quarter ended June 30, 2010
10-Q	Quarter ended March 31, 2010
10-K	Fiscal year ended Dec. 31, 2009

PROXIES

DEF 14A	Filed on March 28, 2025
DEF 14A	Filed on March 22, 2024
DEF 14A	Filed on March 24, 2023
DEF 14A	Filed on March 25, 2022
DEF 14A	Filed on March 26, 2021
DEF 14A	Filed on March 27, 2020
DEF 14A	Filed on March 22, 2019
DEF 14A	Filed on March 22, 2018
DEF 14A	Filed on March 22, 2017
DEF 14A	Filed on March 22, 2016
DEF 14A	Filed on March 24, 2015
DEF 14A	Filed on March 25, 2014
DEF 14A	Filed on March 26, 2013
DEF 14A	Filed on March 20, 2012
DEF 14A	Filed on March 18, 2011
DEF 14A	Filed on March 19, 2010

10-Q 1 a13-7847_110q.htm 10-Q

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549-1004

FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2013

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM TO

____________________________________________________________________________

COMMISSION FILE NUMBER 1-11846

AptarGroup, Inc.

DELAWARE		36-3853103
(State of Incorporation)		(I.R.S. Employer Identification No.)

475 WEST TERRA COTTA AVENUE, SUITE E, CRYSTAL LAKE, ILLINOIS 60014

815-477-0424

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer þ		Accelerated filer ¨		Non-accelerated filer ¨		Smaller reporting company ¨
				(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No þ

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date

Class		Outstanding at May 1, 2013
Common Stock, $.01 par value per share		66,696,356 shares

Table of Contents

AptarGroup, Inc.

Form 10-Q

Quarter Ended March 31, 2013

INDEX

Part I.	FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited)

	Condensed Consolidated Statements of Income - Three Months Ended March 31, 2013 and 2012	1

	Condensed Consolidated Statements of Comprehensive (Loss) Income - Three Months Ended March 31, 2013 and 2012	2

	Condensed Consolidated Balance Sheets – March 31, 2013 and December 31, 2012	3

	Condensed Consolidated Statements of Changes in Equity - Three Months Ended March 31, 2013 and 2012	5

	Condensed Consolidated Statements of Cash Flows - Three Months Ended March 31, 2013 and 2012	6

	Notes to Condensed Consolidated Financial Statements	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	23

Item 4.	Controls and Procedures	23

Part II.	OTHER INFORMATION

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	24

Item 6.	Exhibits	25

	Signature	26

Table of Contents

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

AptarGroup, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

In thousands, except per share amounts

Three Months Ended March 31,	2013			2012

Net Sales	$	617,633		$	592,498
Operating Expenses:
Cost of sales (exclusive of depreciation and amortization shown below)	418,486			401,070
Selling, research & development and administrative	94,307			88,499
Depreciation and amortization	36,171			32,554
Restructuring initiatives	4,067			--
	553,031			522,123
Operating Income	64,602			70,375

Other Income (Expense):
Interest expense	(5,081		)	(5,242		)
Interest income	849			1,028
Equity in results of affiliates	(262		)	(131		)
Miscellaneous, net	(706		)	247
	(5,200		)	(4,098		)

Income before Income Taxes	59,402			66,277

Provision for Income Taxes	19,424			22,464

Net Income	39,978			43,813

Net Loss/(Income) Attributable to Noncontrolling Interests	51			(4		)

Net Income Attributable to AptarGroup, Inc.	$	40,029		$	43,809

Net Income Attributable to AptarGroup, Inc. Per Common Share:
Basic	$	0.61		$	0.66
Diluted	$	0.59		$	0.64

Average Number of Shares Outstanding:
Basic	66,155			66,196
Diluted	68,296			68,785

Dividends per Common Share	$	0.25		$	0.22

See accompanying unaudited notes to condensed consolidated financial statements.

Table of Contents

AptarGroup, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME

(Unaudited)

In thousands, except per share amounts

Three Months Ended March 31,	2013			2012

Net Income	$	39,978		$	43,813
Other Comprehensive Income:
Foreign currency translation adjustments	(35,613		)	41,682
Changes in treasury locks, net of tax	15			15
Net gain on derivatives, net of tax	--			(7		)
Defined benefit pension plan, net of tax
Amortization of prior service cost included in net income, net of tax	61			61
Amortization of net loss included in net income, net of tax	1,118			687
Total defined benefit pension plan, net of tax	1,179			748
Total other comprehensive (loss) income	(34,419		)	42,438

Comprehensive Income	5,559			86,251

Comprehensive Loss/(Income) Attributable to Noncontrolling Interests	50			(3		)

Comprehensive Income Attributable to AptarGroup, Inc.	$	5,609		$	86,248

See accompanying unaudited notes to condensed consolidated financial statements.

Table of Contents

AptarGroup, Inc.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

In thousands, except per share amounts

	March 31,			December 31,
	2013			2012
Assets

Current Assets:
Cash and equivalents	$	225,104		$	229,755
Accounts and notes receivable, less allowance for doubtful accounts of $6,147 in 2013 and $6,751 in 2012	441,284			396,788
Inventories	326,248			321,885
Prepaid and other	98,762			90,505
	1,091,398			1,038,933

Property, Plant and Equipment:
Buildings and improvements	363,859			364,704
Machinery and equipment	1,840,679			1,857,347
	2,204,538			2,222,051
Less: Accumulated depreciation	(1,392,893		)	(1,397,575		)
	811,645			824,476
Land	23,333			23,757
	834,978			848,233

Other Assets:
Investments in affiliates	3,347			3,693
Goodwill	344,712			351,552
Intangible assets, net	49,843			51,960
Miscellaneous	28,292			30,041
	426,194			437,246
Total Assets	$	2,352,570		$	2,324,412

See accompanying unaudited notes to condensed consolidated financial statements.

AptarGroup, Inc.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

In thousands, except per share amounts

	March 31,			December 31,
	2013			2012
Liabilities and Stockholders’ Equity

Current Liabilities:
Notes payable	$	60,488		$	45,166
Current maturities of long-term obligations	28,405			29,488
Accounts payable and accrued liabilities	388,585			380,669
	477,478			455,323

Long-Term Obligations	352,749			352,860

Deferred Liabilities and Other:
Deferred income taxes	29,897			33,451
Retirement and deferred compensation plans	97,533			95,872
Deferred and other non-current liabilities	7,143			6,408
Commitments and contingencies	--			--
	134,573			135,731

Stockholders’ Equity:
AptarGroup, Inc. stockholders’ equity
Preferred stock, $.01 par value, 1 million shares authorized, none outstanding	--			--
Common stock, $.01 par value, 199 million shares authorized; 84.6 and 84.1 million shares issued as of March 31, 2013 and December 31, 2012, respectively	845			840
Capital in excess of par value	459,178			430,210
Retained earnings	1,537,094			1,513,558
Accumulated other comprehensive income	26,263			60,683
Less treasury stock at cost, 18.2 and 18.2 million shares as of March 31, 2013 and December 31, 2012, respectively	(636,168		)	(625,401		)
Total AptarGroup, Inc. Stockholders’ Equity	1,387,212			1,379,890
Noncontrolling interests in subsidiaries	558			608

Total Stockholders’ Equity	1,387,770			1,380,498
Total Liabilities and Stockholders’ Equity	$	2,352,570		$	2,324,412

See accompanying unaudited notes to condensed consolidated financial statements.

AptarGroup, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(Unaudited)

In thousands, except per share amounts

	AptarGroup, Inc. Stockholders’ Equity
				Accumulated
				Other			Common					Capital in		Non-
	Retained			Comprehensive			Stock		Treasury			Excess of		Controlling			Total
	Earnings			Income/(Loss)			Par Value		Stock			Par Value		Interest			Equity

Balance – December 31, 2011:	$	1,409,388		$	60,318		$	827	$	(545,612	)	$	364,855	$	796		$	1,290,572

Net income	43,809													4			43,813
Foreign currency translation adjustments				41,683										(1		)	41,682
Changes in unrecognized pension gains/losses and related amortization, net of tax				748													748
Changes in treasury locks, net of tax				15													15
Net loss on derivatives, net of tax				(7		)											(7		)
Stock option exercises & restricted stock vestings							8		3			32,099					32,110
Cash dividends declared on common stock	(14,530		)														(14,530		)
Treasury stock purchased									(10,096		)						(10,096		)
Balance – March 31, 2012:	$	1,438,667		$	102,757		$	835	$	(555,705	)	$	396,954	$	799		$	1,384,307

Balance – December 31, 2012:	$	1,513,558		$	60,683		$	840	$	(625,401	)	$	430,210	$	608		$	1,380,498

Net income (loss)	40,029													(51		)	39,978
Foreign currency translation adjustments				(35,614		)								1			(35,613		)
Changes in unrecognized pension gains/losses and related amortization, net of tax				1,179													1,179
Changes in treasury locks, net of tax				15													15
Net loss on derivatives, net of tax				--													--
Stock option exercises & restricted stock vestings							5		1			28,968					28,974
Cash dividends declared on common stock	(16,493		)														(16,493		)
Treasury stock purchased									(10,768		)						(10,768		)
Balance – March 31, 2013:	$	1,537,094		$	26,263		$	845	$	(636,168	)	$	459,178	$	558		$	1,387,770

See accompanying unaudited notes to condensed consolidated financial statements.

AptarGroup, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

In thousands, brackets denote cash outflows

Three Months Ended March 31,	2013			2012

Cash Flows from Operating Activities:
Net income	$	39,978		$	43,813
Adjustments to reconcile net income to net cash provided by operations:
Depreciation	34,934			32,205
Amortization	1,237			349
Stock option based compensation	6,534			5,774
(Recovery)/Provision for doubtful accounts	(311		)	(721		)
Deferred income taxes	(4,668		)	(252		)
Defined benefit plan expense	5,123			3,585
Equity in results of affiliates in excess of cash distributions received	262			131
Changes in balance sheet items, excluding effects from foreign currency adjustments:
Accounts receivable	(52,022		)	(42,498		)
Inventories	(9,720		)	(8,818		)
Prepaid and other current assets	(8,947		)	265
Accounts payable and accrued liabilities	5,528			5,015
Income taxes payable	4,509			4,033
Retirement and deferred compensation plans	(3,118		)	(6,338		)
Other changes, net	6,790			(22,885		)
Net Cash Provided/(Used) by Operations	26,109			13,658

Cash Flows from Investing Activities:
Capital expenditures	(34,832		)	(42,496		)
Disposition of property and equipment	2,162			771
Investment in unconsolidated affiliate	--			(279		)
Notes receivable, net	--			20
Net Cash Used by Investing Activities	(32,670		)	(41,984		)

Cash Flows from Financing Activities:
Proceeds/(Repayments) from notes payable	14,754			(31,967		)
Repayments of long-term obligations	(585		)	(761		)
Dividends paid	(16,493		)	(14,530		)
Credit facility costs	(497		)	(1,121		)
Proceeds from stock option exercises	19,540			19,674
Purchase of treasury stock	(10,768		)	(10,096		)
Excess tax benefit from exercise of stock options	2,403			6,433
Net Cash Provided/(Used) by Financing Activities	8,354			(32,368		)

Effect of Exchange Rate Changes on Cash	(6,444		)	12,883

Net Decrease in Cash and Equivalents	(4,651		)	(47,811		)
Cash and Equivalents at Beginning of Period	229,755			377,616
Cash and Equivalents at End of Period	$	225,104		$	329,805

See accompanying unaudited notes to condensed consolidated financial statements.

AptarGroup, Inc.

Notes to Condensed Consolidated Financial Statements

(Amounts in Thousands, Except per Share Amounts, or Otherwise Indicated)

(Unaudited)

NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements include the accounts of AptarGroup, Inc. and its subsidiaries. The terms “AptarGroup” or “Company” as used herein refer to AptarGroup, Inc. and its subsidiaries. All significant intercompany accounts and transactions have been eliminated.

In the opinion of management, the unaudited condensed consolidated financial statements include all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of consolidated financial position, results of operations, comprehensive income, changes in equity and cash flows for the interim periods presented. The accompanying unaudited condensed consolidated financial statements have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosure normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures made are adequate to make the information presented not misleading. Also, certain financial position data included herein was derived from the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012 but does not include all disclosures required by accounting principles generally accepted in the United States of America. Accordingly, these unaudited condensed consolidated financial statements and related notes should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012. The results of operations of any interim period are not necessarily indicative of the results that may be expected for the year.

ADOPTION OF RECENT ACCOUNTING PRONOUNCEMENTS

Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of accounting standards updates to the FASB’s Accounting Standards Codification.

In February 2013, The FASB issued authoritative guidance that amends the presentation of accumulated other comprehensive income and clarifies how to report the effect of significant reclassifications out of accumulated other comprehensive income. The guidance requires footnote disclosures regarding the changes in accumulated other comprehensive income by component and the line items affected in the statements of earnings. The adoption of this standard had no impact on the Condensed Consolidated Financial Statements other than disclosure. Additional information can be found in Note 5 of the Notes to the Condensed Consolidated Financial Statements.

In January 2013, The FASB issued authoritative guidance requiring new asset and liability offsetting disclosures for derivatives, repurchase agreements and security lending transactions to the extent that they are offset in the financial statements or are subject to an enforceable master netting arrangement or similar agreement. We do not have any repurchase agreements and do not participate in securities lending transactions. Our derivative instruments are not offset in the financial statements. Accordingly, the adoption of this standard had no impact on the Condensed Consolidated Financial Statements other than disclosure. Additional information can be found in Note 6 of the Notes to the Condensed Consolidated Financial Statements.

INCOME TAXES

The Company computes taxes on income in accordance with the tax rules and regulations of the many taxing authorities where the income is earned. The income tax rates imposed by these taxing authorities may vary substantially. Taxable income may differ from pretax income for financial accounting purposes. To the extent that these differences create differences between the tax basis of an asset or liability and its reported amount in the financial statements, an appropriate provision for deferred income taxes is made.

In its determination of which foreign earnings are permanently reinvested in foreign operations, the Company considers numerous factors, including the financial requirements of the U.S. parent company and those of its foreign subsidiaries, the U.S. funding needs for dividend payments and stock repurchases, and the tax consequences of remitting earnings to the U.S. From this analysis, current year repatriation decisions are made in an attempt to provide a proper mix of debt and shareholder capital both within the U.S. and for non-U.S. operations. The Company’s policy is to permanently reinvest its accumulated foreign earnings and only will make a distribution out of current year earnings to meet the cash needs at the parent company. As such, the Company does not provide for taxes on earnings that are deemed to be permanently reinvested. The effective tax rate for 2013 includes the tax cost of repatriating $76 million of current year earnings, all of which is expected to be repatriated in the first half of 2013.

The Company provides a liability for the amount of tax benefits realized from uncertain tax positions. This liability is provided whenever the Company determines that a tax benefit will not meet a more-likely-than-not threshold for recognition. See Note 13 of the Notes to the Condensed Consolidated Financial Statements for more information.

NOTE 2 - INVENTORIES

At March 31, 2013 and December 31, 2012, approximately 18% and 19%, respectively, of the total inventories are accounted for by the LIFO method. Inventories, by component, consisted of:

	March 31,			December 31,
	2013			2012

Raw materials	$	118,037		$	125,889
Work in process	89,188			75,261
Finished goods	126,186			127,393
Total	333,411			328,543
Less LIFO Reserve	(7,163		)	(6,658		)
Total	$	326,248		$	321,885

NOTE 3 – GOODWILL AND OTHER INTANGIBLE ASSETS

The changes in the carrying amount of goodwill since the year ended December 31, 2012 are as follows by reporting segment:

	Beauty +						Food +			Corporate
	Home			Pharma			Beverage			& Other			Total

Goodwill	$	179,890		$	153,978		$	17,684		$	1,615		$	353,167
Accumulated impairment losses	--			--			--			(1,615		)	(1,615		)
Balance as of December 31, 2012	$	179,890		$	153,978		$	17,684		$	--		$	351,552
Acquisition	--			--			--			--			--
Foreign currency exchange effects	(2,245		)	(4,386		)	(209		)	--			(6,840		)
Goodwill	$	177,645		$	149,592		$	17,475		$	1,615		$	346,327
Accumulated impairment losses	--			--			--			(1,615		)	(1,615		)
Balance as of March 31, 2013	$	177,645		$	149,592		$	17,475		$	--		$	344,712

The table below shows a summary of intangible assets as of March 31, 2013 and December 31, 2012.

		March 31, 2013							December 31, 2012

Weighted Average		Gross							Gross
Amortization		Carrying		Accumulated			Net		Carrying		Accumulated			Net
Period (Years)		Amount		Amortization			Value		Amount		Amortization			Value

Amortized intangible assets:
Patents	11	$	19,041	$	(18,435	)	$	606	$	19,570	$	(18,894	)	$	676
Acquired Technology	15	37,820		(1,891		)	35,929		38,928		(1,298		)	37,630
License agreements and other	5	35,216		(21,908		)	13,308		35,780		(22,126		)	13,654
Total intangible assets	10	$	92,077	$	(42,234	)	$	49,843	$	94,278	$	(42,318	)	$	51,960

Aggregate amortization expense for the intangible assets above for the quarters ended March 31, 2013 and 2012 was $1,237 and $349, respectively.

Future estimated amortization expense for the years ending December 31 is as follows:

2013	$	3,659	(remaining estimated amortization for 2013)
2014	4,862
2015	4,689
2016	4,059
2017 and thereafter	32,574

Future amortization expense may fluctuate depending on changes in foreign currency rates. The estimates for amortization expense noted above are based upon foreign exchange rates as of March 31, 2013.

NOTE 4 – RETIREMENT AND DEFERRED COMPENSATION PLANS

Components of Net Periodic Benefit Cost:

	Domestic Plans						Foreign Plans
Three months ended March 31,	2013			2012			2013			2012

Service cost	$	2,225		$	1,804		$	969		$	519
Interest cost	1,250			1,228			665			645
Expected return on plan assets	(1,414		)	(1,401		)	(452		)	(388		)
Amortization of net loss	1,434			964			352			121
Amortization of prior service cost	1			1			93			92
Net periodic benefit cost	$	3,496		$	2,596		$	1,627		$	989

Table of Contents

EMPLOYER CONTRIBUTIONS

In order to meet or exceed minimum funding levels required by U.S. law, the Company expects to contribute approximately $10 million to its domestic defined benefit plans in 2013 and has not made any 2013 contributions as of March 31, 2013. The Company also expects to contribute approximately $4.3 million to its foreign defined benefit plans in 2013 and, as of March 31, 2013, has contributed approximately $0.7 million.

NOTE 5 – ACCUMULATED OTHER COMPREHENSIVE INCOME

Changes in Accumulated Other Comprehensive Income by Component:

	Foreign			Defined Benefit
	Currency			Pension Plans			Other			Total
Balance – December 31, 2011	$	100,593		$	(39,907	)	$	(368	)	$	60,318
Other comprehensive income before reclassifications	41,683			--			--			41,683
Amounts reclassified from accumulated other comprehensive income	--			748			8			756
Net current-period other comprehensive income	41,683			748			8			42,439
Balance - March 31, 2012	$	142,276		$	(39,159	)	$	(360	)	$	102,757

Balance – December 31, 2012	$	120,097		$	(59,248	)	$	(166	)	$	60,683
Other comprehensive income before reclassifications	(35,614		)	--			--			(35,614		)
Amounts reclassified from accumulated other comprehensive income	--			1,179			15			1,194
Net current-period other comprehensive income	(35,614		)	1,179			15			(34,420		)
Balance - March 31, 2013	$	84,483		$	(58,069	)	$	(151	)	$	26,263

Reclassifications Out of Accumulated Other Comprehensive Income:

Details about Accumulated Other	Amount Reclassified from Accumulated						Affected Line in the Statement
Comprehensive Income Components	Other Comprehensive Income						Where Net Income is Presented
Three months ended March 31,	2013			2012

Defined Benefit Pension Plans
Amortization of net loss	$	1,786		$	1,085			(a)
Amortization of prior service cost	94			93				(a)
	1,880			1,178				Total before tax
	(701		)	(430		)		Tax benefit
	$	1,179		$	748			Net of tax


Other
Changes in treasury locks	23			23				Interest Expense
Net loss on derivatives	--			(10		)		Interest Income
	23			13				Total before tax
	(8		)	(5		)		Tax benefit
	$	15		$	8			Net of tax

Total reclassifications for the period	$	1,194		$	756

(a)	These accumulated other comprehensive income components are included in the computation of net periodic benefit costs, net of tax (see Note 4 – Retirement and Deferred Compensation Plans for additional details).

NOTE 6 – DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

The Company maintains a foreign exchange risk management policy designed to establish a framework to protect the value of the Company’s non-functional denominated transactions from adverse changes in exchange rates. Sales of the Company’s products can be denominated in a currency different from the currency in which the related costs to produce the product are

Table of Contents

denominated. Changes in exchange rates on such inter-country sales or intercompany loans can impact the Company’s results of operations. The Company’s policy is not to engage in speculative foreign currency hedging activities, but to minimize its net foreign currency transaction exposure defined as firm commitments and transactions recorded and denominated in currencies other than the functional currency. The Company may use foreign currency forward exchange contracts, options and cross currency swaps to economically hedge these risks.

The Company maintains an interest rate risk management strategy to minimize significant, unanticipated earnings fluctuations that may arise from volatility in interest rates.

For derivative instruments designated as hedges, the Company formally documents the nature and relationships between the hedging instruments and the hedged items, as well as the risk management objectives, strategies for undertaking the various hedge transactions, and the method of assessing hedge effectiveness. Additionally, in order to designate any derivative instrument as a hedge of an anticipated transaction, the significant characteristics and expected terms of any anticipated transaction must be specifically identified, and it must be probable that the anticipated transaction will occur.

CASH FLOW HEDGES

The Company had one foreign currency cash flow hedge until March 15, 2012. A French subsidiary of AptarGroup, AptarGroup Holding SAS, had hedged the risk of variability in Euro equivalent associated with the cash flows of an intercompany loan granted in Brazilian Real. The forward contracts utilized were designated as a hedge of the changes in the cash flows relating to the changes in foreign currency rates relating to the loan and related forecasted interest. On March 15, 2012, the loan and foreign currency forward contracts were repaid.

HEDGE OF NET INVESTMENTS IN FOREIGN OPERATIONS

A significant number of the Company’s operations are located outside of the United States. Because of this, movements in exchange rates may have a significant impact on the translation of the financial condition and results of operations of the Company’s foreign entities. A strengthening U.S. dollar relative to foreign currencies has a dilutive translation effect on the Company’s financial condition and results of operations. Conversely, a weakening U.S. dollar has an additive effect. The Company in some cases maintains debt in these subsidiaries to offset the net asset exposure. The Company does not otherwise actively manage this risk using derivative financial instruments. In the event the Company plans on a full or partial liquidation of any of its foreign subsidiaries where the Company’s net investment is likely to be monetized, the Company will consider hedging the currency exposure associated with such a transaction.

OTHER

As of March 31, 2013, the Company has recorded the fair value of foreign currency forward exchange contracts of $1.1 million in prepaid and other, $2.7 million in accounts payable and accrued liabilities, and $0.9 million in deferred and other non-current liabilities in the balance sheet. All forward exchange contracts outstanding as of March 31, 2013 had an aggregate contract amount of $104 million.

Fair Value of Derivative Instruments in the Condensed Consolidated Balance Sheets as of March 31, 2013

and December 31, 2012

Derivative Contracts Not Designated as Hedging Instruments	Balance Sheet Location	March 31, 2013		December 31, 2012

Derivative Assets
Foreign Exchange Contracts	Prepaid and other	$	1,142	$	332
Foreign Exchange Contracts	Miscellaneous Other Assets	--		982
		$	1,142	$	1,314
Derivative Liabilities
Foreign Exchange Contracts	Accounts payable and accrued liabilities	$	2,669	$	2,097
Foreign Exchange Contracts	Deferred and other non-current liabilities	948		164
		$	3,617	$	2,261

The Effect of Derivative Instruments on the Condensed Consolidated Statements of Income

for the Quarters Ended March 31, 2013 and March 31, 2012

Derivatives Not Designated as Hedging Instruments	Location of Gain or (Loss) Recognized in Income on Derivative	Amount of Gain or (Loss) Recognized in Income on Derivative
		2013			2012
Foreign Exchange Contracts	Other Income (Expense) Miscellaneous, net	$	(2,598	)	$	7,116
		$	(2,598	)	$	7,116

Table of Contents

			Net Amounts	Gross Amounts not Offset in the
		Gross Amounts	Presented in	Statement of Financial Position
	Gross	Offset in the	the Statement of	Financial	Cash Collateral	Net
	Amount	Financial Position	Financial Position	Instruments	Received	Amount
Description
2013
Derivative Assets	$1,142	--	$1,142	--	--	$1,142
Total Assets	$1,142	--	$1,142	--	--	$1,142

Derivative Liabilities	$3,617	--	$3,617	--	--	$3,617
Total Liabilities	$3,617	--	$3,617	--	--	$3,617

2012
Derivative Assets	$1,314	--	$1,314	--	--	$1,314
Total Assets	$1,314	--	$1,314	--	--	$1,314

Derivative Liabilities	$2,261	--	$2,261	--	--	$2,261
Total Liabilities	$2,261	--	$2,261	--	--	$2,261

NOTE 7 – COMMITMENTS AND CONTINGENCIES

The Company, in the normal course of business, is subject to a number of lawsuits and claims both actual and potential in nature including the proceeding noted below. While management believes the resolution of these claims and lawsuits will not have a material adverse effect on the Company’s financial position or results of operations or cash flows, claims and legal proceedings are subject to inherent uncertainties, and unfavorable outcomes could occur that could include amounts in excess of any accruals which management has established. Were such unfavorable final outcomes to occur, it is possible that they could have a material adverse effect on our financial position, results of operations and cash flows.

In 2010, a competitor filed a lawsuit against certain AptarGroup, Inc. subsidiaries alleging that certain processes performed by a supplier of a specific type of diptube utilized by the AptarGroup, Inc. subsidiaries in the manufacture of a specific type of pump infringes patents owned by the counterparty. This lawsuit sought an injunction barring the manufacture, use, sale and importation of this specific pump for use in fragrance containers. In April 2012, the Company’s United States subsidiary was found to have infringed on patents owned by the counterparty within the United States. The ruling does not apply to manufacture or sales of pumps in countries outside the United States and no damages were assessed. The Company has appealed this ruling and is waiting for a court decision.

Under its Certificate of Incorporation, the Company has agreed to indemnify its officers and directors for certain events or occurrences while the officer or director is, or was serving, at its request in such capacity. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company has a directors and officers liability insurance policy that covers a portion of its exposure. As a result of its insurance policy coverage, the Company believes the estimated fair value of these indemnification agreements is minimal. The Company has no liabilities recorded for these agreements as of March 31, 2013.

NOTE 8 – STOCK REPURCHASE PROGRAM

During the three months ended March 31, 2013, the Company repurchased approximately 201 thousand shares for an aggregate amount of $10.8 million. As of March 31, 2013, the Company has a remaining authorization to repurchase 1.8 million additional shares. The timing of and total amount expended for the share repurchase depends upon market conditions.

NOTE 9 – EARNINGS PER SHARE

AptarGroup’s authorized common stock consists of 199 million shares, having a par value of $.01 each. Information related to the calculation of earnings per share is as follows:

	March 31, 2013				March 31, 2012
	Diluted		Basic		Diluted		Basic

Consolidated operations
Income available to common shareholders	$	40,029	$	40,029	$	43,809	$	43,809

Average equivalent shares
Shares of common stock	66,155		66,155		66,196		66,196
Effect of dilutive stock based compensation
Stock options	2,133		--		2,580		--
Restricted stock	8		--		9		--
Total average equivalent shares	68,296		66,155		68,785		66,196
Net income per share	$	.59	$	.61	$	.64	$	.66

Table of Contents

NOTE 10 – SEGMENT INFORMATION

The Company operates in the packaging components industry, which includes the development, manufacture and sale of consumer product dispensing systems. The Company is organized into three reporting segments. Operations that sell dispensing systems primarily to the personal care, fragrance/cosmetic and home care markets form the Beauty + Home segment. Operations that sell dispensing systems primarily to the prescription drug and consumer health care markets form the Pharma segment. Operations that sell dispensing systems primarily to the food and beverage markets form the Food + Beverage segment.

The accounting policies of the segments are the same as those described in Note 1, Summary of Significant Accounting Policies in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012. Segment income is defined as earnings before net interest expense, certain corporate expenses, restructuring initiatives and related depreciation and income taxes.

Financial information regarding the Company’s reportable segments is shown below:

Three months ended March 31,	2013			2012

Total Revenue:
Beauty + Home	$	367,183		$	380,836
Pharma	168,893			140,201
Food + Beverage	85,333			75,822
Total Revenue	$	621,409		$	596,859

Less: Intersegment Sales:
Beauty + Home	$	3,711		$	3,685
Pharma	24			158
Food + Beverage	41			518
Total Intersegment Sales	$	3,776		$	4,361

Net Sales:
Beauty + Home	$	363,472		$	377,151
Pharma	168,869			140,043
Food + Beverage	85,292			75,304
Net Sales	$	617,633		$	592,498

Segment Income (1):
Beauty + Home	$	24,415		$	32,972
Pharma	45,980			39,372
Food + Beverage	8,550			6,788
Restructuring Initiatives and Related Depreciation	(4,526		)	–
Corporate & Other	(10,785		)	(8,641		)
Income before interest and taxes	$	63,634		$	70,491
Interest expense, net	(4,232		)	(4,214		)
Income before income taxes	$	59,402		$	66,277

(1) The Company evaluates performance of its business units and allocates resources based upon segment income. Segment income is defined as earnings before net interest expense, certain corporate expenses, restructuring initiatives and income taxes. Restructuring Initiatives and Related Depreciation includes the following income/(expense) items for the three months ended March 31, 2013 as follows:

Three months ended March 31,	2013		2012

European Operations Optimization (“EOO”) Plan
Depreciation	$	459	$	--
Employee Severance and Other Costs	4,067		--
Total Restructuring Initiatives and Related Depreciation Expense	$	4,526	$	--

Restructuring Initiatives and Related Depreciation Expense by Segment
Beauty + Home	$	4,526	$	--
Total Restructuring Initiatives and Related Depreciation Expense	$	4,526	$	--

Table of Contents

NOTE 11 – ACQUISITIONS

On July 3, 2012, the Company completed its acquisition of Rumpler - Technologies S.A., together with its direct and indirect subsidiaries (“Stelmi”). Stelmi is a producer of elastomer primary packaging components for injectable drug delivery and operates two manufacturing plants located in the Normandy region of France and also has a research and development facility located near Paris. The Company acquired all of the shares of Stelmi. The purchase price paid for Stelmi (net of cash acquired) was approximately $188 million and was funded by cash on hand.

Stelmi contributed sales of $35.4 million and a pretax income of $7.0 million for the three months ended March 31, 2013. The results of the acquired business for the period from the acquisition date are included in the accompanying consolidated financial statements and are reported in the Pharma reporting segment.

The following table summarizes the assets acquired and liabilities assumed as of the acquisition date at estimated fair value. If additional information is obtained about these assets and liabilities within the measurement period (not to exceed one year from the date of acquisition), the Company may refine its estimates of fair value to allocate the purchase price more accurately; however, any such revisions are not expected to be significant.

	July 3, 2012
Assets
Cash and equivalents	$	68,335
Accounts receivable	23,540
Inventories	16,826
Prepaid and other	3,256
Property, plant and equipment	42,073
Goodwill	111,031
Intangible assets	47,134
Other miscellaneous assets	6,092

Liabilities
Current maturities of long-term obligations	675
Accounts payable and accrued liabilities	26,064
Long-term obligations	885
Deferred income taxes	22,440
Retirement and deferred compensation plans	12,049
Net assets acquired	$	256,174

The following table is a summary of the fair value estimates of the acquired identifiable intangible assets and weighted-average useful lives as of the acquisition date:

	Weighted-Average	Estimated
	Useful Life	Fair Value
	(in years)	of Asset

Customer relationships	15	$	7,438
Technology	15	37,191
Trademark	4	2,505
Total		$	47,134

Goodwill in the amount of $111.0 million was recorded for the acquisition of Stelmi and is included in the Pharma segment. Goodwill is calculated as the excess of the consideration transferred over the net assets acquired and represents the estimated future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Goodwill largely consists of leveraging the Company’s commercial presence in selling the Stelmi line of products in markets where Stelmi didn’t previously operate and the ability of Stelmi to maintain its competitive advantage from a technical viewpoint. Goodwill will not be amortized, but will be tested for impairment at least annually. We do not expect that any of the goodwill will be deductible for tax purposes.

The unaudited pro forma results presented below include the effects of the Stelmi acquisition as if it had occurred as of January 1, 2011. The unaudited pro forma results reflect certain adjustments related to the acquisition, such as the amortization associated with estimates for the acquired intangible assets and fair value adjustments for inventory. The pro forma results do not include any synergies or other expected benefits of the acquisition. Accordingly, the unaudited pro forma financial information below is not necessarily indicative of either future results of operations or results that might have been achieved had the acquisition been completed on the dates indicated.

	Three Months Ended March 31,
	2013		2012

Net Sales	$	617,633	$	625,474
Net Income Attributable to AptarGroup Inc.	40,037		46,530
Net Income per common share - basic	0.61		0.70
Net Income per common share - diluted	0.59		0.68

Table of Contents

NOTE 12 – STOCK-BASED COMPENSATION

The Company issues stock options and restricted stock units to employees under Stock Awards Plans approved by shareholders. Stock options are issued to non-employee directors for their services as directors under Director Stock Option Plans approved by shareholders. Options are awarded with the exercise price equal to the market price on the date of grant and generally become exercisable over three years and expire 10 years after grant. Restricted stock units generally vest over three years.

Compensation expense recorded attributable to stock options for the first three months of 2013 was approximately $6.5 million ($4.4 million after tax), or $0.07 per basic share and $0.06 per diluted share. The income tax benefit related to this compensation expense was approximately $2.1 million. Approximately $5.9 million of the compensation expense was recorded in selling, research & development and administrative expenses and the balance was recorded in cost of sales. Compensation expense recorded attributable to stock options for the first three months of 2012 was approximately $5.8 million ($3.9 million after tax), or $0.06 per basic and diluted share. The income tax benefit related to this compensation expense was approximately $1.9 million. Approximately $5.3 million of the compensation expense was recorded in selling, research & development and administrative expenses and the balance was recorded in cost of sales.

The Company uses historical data to estimate expected life and volatility. The weighted-average fair value of stock options granted under the Stock Awards Plans was $10.07 and $10.35 per share in 2013 and 2012, respectively. These values were estimated on the respective dates of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions:

Stock Awards Plans:
Three months ended March 31,	2013		2012

Dividend Yield	1.8	%	1.8	%
Expected Stock Price Volatility	22.7	%	22.9	%
Risk-free Interest Rate	1.2	%	1.3	%
Expected Life of Option (years)	6.9		6.9

There were no grants under the Director Stock Option Plan during the three months ended March 31, 2013 and 2012.

A summary of option activity under the Company’s stock option plans as of March 31, 2013, and changes during the three months then ended is presented below:

Stock Awards Plans

Director Stock Option Plans

Weighted Average

Shares

Exercise Price

Shares

Exercise Price

Outstanding, January 1, 2013

7,879,197

37.27

276,667

45.48

Granted

1,335,300

51.57

Exercised

(663,664

)

28.69

Forfeited or expired

(22,966

)

45.02

Outstanding at March 31, 2013

8,527,867

40.15

276,667

45.48

Exercisable at March 31, 2013

5,982,854

35.49

121,834

38.09

Weighted-Average Remaining Contractual Term (Years):

Outstanding at March 31, 2013

6.5

7.6

Exercisable at March 31, 2013

5.4

6.3

Aggregate Intrinsic Value ($000):

Outstanding at March 31, 2013

146,648

3,283

Exercisable at March 31, 2013

130,756

2,347

Intrinsic Value of Options Exercised ($000) During the Three Months Ended:

March 31, 2013

16,515

March 31, 2012

21,524

509

The fair value of shares vested during the three months ended March 31, 2013 and 2012 was $12.1 million and $11.4 million, respectively. Cash received from option exercises was approximately $19.5 million and the actual tax benefit realized for the tax deduction from option exercises was approximately $4.0 million in the three months ended March 31, 2013. As of March 31, 2013, the remaining valuation of stock option awards to be expensed in future periods was $15.3 million and the related weighted-average period over which it is expected to be recognized is 1.6 years.

The fair value of restricted stock unit grants is the market price of the underlying shares on the grant date. A summary of restricted stock unit activity as of March 31, 2013, and changes during the period then ended is presented below:

Table of Contents

			Weighted-Average
	Shares		Grant-Date Fair Value

Nonvested at January 1, 2013	25,862		$	48.76
Granted	9,948		53.94
Vested	(11,208	)	44.27
Nonvested at March 31, 2013	24,602		$	52.90

Compensation expense recorded attributable to restricted stock unit grants for the first three months of 2013 and 2012 was approximately $416 thousand and $219 thousand, respectively. The fair value of units vested during the three months ended March 31, 2013 and 2012 was $496 thousand and $316 thousand, respectively. The intrinsic value of units vested during the three months ended March 31, 2013 and 2012 was $582 thousand and $448 thousand, respectively. As of March 31, 2013 there was $622 thousand of total unrecognized compensation cost relating to restricted stock unit awards which is expected to be recognized over a weighted-average period of 1.6 years.

NOTE 13 – INCOME TAX UNCERTAINTIES

The Company had approximately $8.4 and $8.5 million recorded for income tax uncertainties as of March 31, 2013 and December 31, 2012, respectively. The $0.1 million change in income tax uncertainties was primarily the result of currency changes. The amount, if recognized, that would impact the effective tax rate is $8.0 and $8.1 million, respectively. The Company estimates that it is reasonably possible that the liability for uncertain tax positions will decrease by no more than $ 5 million in the next twelve months from the resolution of various uncertain positions as a result of the completion of tax audits, litigation and the expiration of the statute of limitations in various jurisdictions.

NOTE 14 – FAIR VALUE

Authoritative guidelines require the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment. The three levels are defined as follows:

·	Level 1: Unadjusted quoted prices in active markets for identical assets and liabilities.
·	Level 2: Observable inputs other than those included in Level 1. For example, quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets.
·	Level 3: Unobservable inputs reflecting management’s own assumptions about the inputs used in pricing the asset or liability.

As of March 31, 2013, the fair values of our financial assets and liabilities were categorized as follows:

	Total		Level 1		Level 2		Level 3
*Assets*
Forward exchange contracts (a)	$	1,142	$	--	$	1,142	$	--
Total assets at fair value	$	1,142	$	--	$	1,142	$	--

*Liabilities*
Forward exchange contracts (a)	$	3,617	$	--	$	3,617	$	--
Total liabilities at fair value	$	3,617	$	--	$	3,617	$	--

As of December 31, 2012, the fair values of our financial assets and liabilities were categorized as follows:

	Total		Level 1		Level 2		Level 3
*Assets*
Forward exchange contracts (a)	$	1,314	$	--	$	1,314	$	--
Total assets at fair value	$	1,314	$	--	$	1,314	$	--

*Liabilities*
Forward exchange contracts (a)	$	2,261	$	--	$	2,261	$	--
Total liabilities at fair value	$	2,261	$	--	$	2,261	$	--

(a) Market approach valuation technique based on observable market transactions of spot and forward rates

The carrying amounts of the Company’s other current financial instruments such as cash and equivalents, notes payable and current maturities of long-term obligations approximate fair value due to the short-term maturity of the instrument. The Company considers its long-term obligations a Level 2 liability and utilizes the market approach valuation technique based on interest rates that are currently available to the Company for issuance of debt with similar terms and maturities. The estimated fair value of the Company’s long-term obligations was $380 million as of March 31, 2013 and $382 million as of December 31, 2012.

Table of Contents

NOTE 15 – RESTRUCTURING INITIATIVE

On November 1, 2012, the Company announced a plan to optimize certain capacity in Europe (EOO). Due to increased production efficiencies and to better position the Company for future growth in Europe, AptarGroup will transfer and consolidate production capacity involving twelve facilities. Two facilities, one in Italy and one in Switzerland, are expected to close and will impact approximately 170 employees. The locations involved in the operations optimization plan are facilities that are serving the beauty, personal care, food, beverage, and consumer health care markets. The total costs associated with the plan are estimated to be approximately €14 million (approximately $18 million using current exchange rates) of which approximately €4 million (approximately $6 million using current exchange rates) relates to non-cash expenses and will be included in depreciation and amortization in the Consolidated Statements of Income. As of March 31, 2013 we have recorded the following activity associated with our EOO plan:

	Beginning		Net Charges for								Ending
	Reserve at		the Three Months								Reserve at
	12/31/12		Ended 3/31/13		Cash Paid			FX Impact			3/31/13

Employee severance	$	3,158	$	3,508	$	(978	)	$	(150	)	$	5,538
Other costs	--		559		(530		)	5			34
Totals	$	3,158	$	4,067	$	(1,508	)	$	(145	)	$	5,572

In addition to the above charges, $0.5 million of accelerated depreciation was incurred in the first quarter of 2013. This amount is included within depreciation and amortization in the Condensed Consolidated Statements of Income.

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

(AMOUNTS IN THOUSANDS, EXCEPT PER SHARE AMOUNTS, OR OTHERWISE INDICATED)

RESULTS OF OPERATIONS

Quarter Ended March 31,	2013		2012

Net Sales	100.0	%	100.0	%
Cost of sales (exclusive of depreciation and amortization shown below)	67.8		67.7
Selling, research & development and administrative	15.3		14.9
Depreciation and amortization	5.9		5.5
Restructuring initiatives	0.6		--
Operating Income	10.4		11.9
Other expense	(0.8	)	(0.7	)
Income before Income Taxes	9.6		11.2

Net Income	6.5	%	7.4	%

Effective Tax Rate	32.7	%	33.9	%

NET SALES

We reported net sales of $617.6 million for the quarter ended March 31, 2013, 4% above first quarter 2012 reported net sales of $592.5 million. Stelmi sales were $35.4 million which contributed 6% to the reported increase in the quarterly sales. The average U.S. dollar exchange rate weakened slightly relative to the Euro. However, this weakness was offset by strengthening of the U.S. dollar compared to other foreign currencies, such as the Brazilian Real, Swiss Franc and British Pound, in the first quarter of 2013 compared to the first quarter of 2012, and as a result, changes in exchange rates had a negative impact of 1% on our reported sales growth. Excluding acquisitions and changes in foreign currency rates, sales decreased by 1% in the first quarter of 2013 compared to the first quarter of 2012. The timing of custom tooling sales accounted for the majority of this decrease.

For further discussion on net sales by reporting segment, please refer to the segment analysis of net sales and segment income on the following pages.

The following table sets forth, for the periods indicated, net sales by geographic location:

Quarter Ended March 31,	2013		% of Total		2012		% of Total

Domestic	$	157,228	25	%	$	171,309	29	%
Europe	356,526		58	%	325,709		55	%
Other Foreign	103,879		17	%	95,480		16	%

COST OF SALES (EXCLUSIVE OF DEPRECIATION SHOWN BELOW)

Our cost of sales as a percent of net sales increased slightly to 67.8% in the first quarter of 2013 compared to 67.7% in the first quarter of 2012. The increase is partially due to decreased sales volumes in our core Pharma segment. This negatively impacts our cost of sales percentage as margins on our pharmaceutical products typically are higher than the overall Company average. Also contributing to the increase in cost of sales percentage is the increase in raw material costs. Raw material costs, primarily the cost of plastic resin, increased in 2013 compared to 2012. While the majority of resin cost increases are passed along to our customers in our selling prices, we typically experience a lag in the timing of passing on these cost increases.

SELLING, RESEARCH & DEVELOPMENT AND ADMINISTRATIVE

Our Selling, Research & Development and Administrative expenses (“SG&A”) increased by approximately $5.8 million in the first quarter of 2013 compared to the same period a year ago. Excluding changes in foreign currency rates, SG&A increased by approximately $6.4 million in the quarter. Stelmi contributed operational costs of $4.7 million in the first quarter of 2013. The remaining increase is due to an increase in personnel costs and stock compensation expenses due to higher substantive vesting requirements. Excluding acquisitions, SG&A as a percentage of net sales increased to 15.4% compared to 14.9% in the same period of the prior year due primarily to lower core sales and the increase in expenses noted above.

Table of Contents

DEPRECIATION AND AMORTIZATION

Reported depreciation and amortization expenses increased by approximately $3.6 million in the first quarter of 2013 compared to the same period a year ago. Excluding changes in foreign currency rates, depreciation and amortization increased by approximately $3.7 million in the quarter compared to the same period a year ago. This increase is primarily related to $2.2 million of Stelmi costs reported in the first quarter of 2013. The remaining increase is related to the additional investments in our new products, especially in the Food + Beverage segment, along with continued roll-out of our global enterprise resource planning system and approximately $0.5 million related to our EOO restructuring initiatives. Excluding acquisitions, depreciation and amortization as a percentage of net sales increased to 5.8% in the first quarter of 2013 compared to 5.5% for the same period a year ago.

RESTRUCTURING INITIATIVES

On November 1, 2012, the Company announced a plan to optimize certain capacity in Europe (“EOO”). Due to increased production efficiencies and to better position the Company for future growth in Europe, AptarGroup will transfer and consolidate production capacity involving twelve facilities. Two facilities, one in Italy and one in Switzerland, are expected to close and will impact approximately 170 employees. During the first quarter of 2013, we recognized $4.1 million of restructuring expenses along with the $0.5 million of accelerated depreciation of assets mentioned above. Using current exchange rates, we expect to recognize approximately $9 million in additional costs, most of which will be incurred in 2013. Annual savings are estimated to be approximately €9 million (approximately $12 million using current exchange rates) beginning in late 2013.

OPERATING INCOME

Operating income decreased approximately $5.8 million in the first quarter of 2013 to $64.6 million compared to $70.4 million in the same period in the prior year. Changes in foreign currency rates had no measureable impact on operating income. Stelmi contributed a $7.1 million operating profit in the first quarter of 2013 and costs associated with the EOO restructuring initiative were $4.5 million. Excluding acquisitions and restructuring initiatives, the remaining $8.4 million decrease to operating income is mainly due to lower core sales and the increase in expenses noted above. Excluding acquisitions and restructuring initiatives, operating income as a percentage of net sales decreased to 10.0% in the first quarter of 2013 compared to 11.9% for the same period in the prior year.

NET OTHER EXPENSE

Net other expenses in the first quarter of 2013 increased to $5.2 million from $4.1 million in the same period in the prior year. This increase is mainly due to increased costs associated with hedges in place to mitigate our foreign currency exposure on cross border transactions.

EFFECTIVE TAX RATE

The reported effective tax rate decreased to 32.7% in the first quarter ended March 31, 2013 compared to 33.9% in the first quarter of 2012. During the first quarter of 2013, the rate was favorably impacted by tax benefits recorded due to an Italian tax law change which allowed us to claim a refund from prior year taxes paid. The favorable impact was partially offset by a new French three percent distribution tax effective for all distributions paid on or after August 17, 2012.

NET INCOME ATTRIBUTABLE TO APTARGROUP, INC.

We reported net income attributable to AptarGroup, Inc. of $40.0 million in the first quarter of 2013 compared to $43.8 million in the first quarter of 2012.

BEAUTY + HOME SEGMENT

Operations that sell dispensing systems primarily to the personal care, fragrance/cosmetic and home care markets form the Beauty + Home segment.

Three Months Ended March 31,	2013			2012

Net Sales	$	363,472		$	377,151
Segment Income	24,415			32,972
Segment Income as a percentage of Net Sales	6.7		%	8.7		%

Net sales for the quarter ended March 31, 2013 decreased 4% to $363.5 million compared to $377.2 million in the first quarter of the prior year. Excluding foreign currency changes, sales decreased 3% in the first quarter of 2013 compared to the same quarter of the prior year. Sales, excluding foreign currency changes, to the beauty and personal care markets were down 2% and 3%, respectively, in the first quarter of 2013 compared to the same period in the prior year. Geographically, sales

Table of Contents

increases in Asia and Latin America were offset by softness in North America caused by a snowstorm on the east coast along with certain unprofitable business we exited. Customer tooling sales, excluding foreign currency changes, also decreased in the first quarter of 2013 to $6.2 million compared to $10.3 million in the first quarter of the prior year.

Segment income for the first quarter of 2013 decreased approximately 26 % to $ 24.4 million from $33.0 million reported in the same period in the prior year. The negative impact of lower product and tooling sales mentioned above along with productivity issues and higher labor costs in North America contributed to this decrease.

PHARMA SEGMENT

Operations that sell dispensing systems to the prescription drug and consumer health care markets form the Pharma segment.

Three Months Ended March 31,	2013			2012

Net Sales	$	168,869		$	140,043
Segment Income	45,980			39,372
Segment Income as a percentage of Net Sales	27.2		%	28.1		%

Net sales for the Pharma segment increased by 21 % in the first quarter of 2013 to $ 168.9 million compared to $140.0 million in the first quarter of 2012. Stelmi sales were $ 35.4 million and represented 25 % of the increase. Foreign currency changes had no measureable impact on the total segment sales. Excluding acquisitions and changes in foreign currency rates, sales decreased by 4 % in the first quarter of 2013 compared to the first quarter of 2012. Excluding acquisitions and foreign currency rate changes, sales to the prescription and consumer health care markets decreased 2% and 9%, respectively, in the first quarter of 2013 compared to the same period in the prior year. The majority of the decrease to the prescription market is due to destocking of inventory by our generic customers, especially in North America, while the decrease in sales to the consumer health care market is due to continued softness in Europe.

Segment income in the first quarter of 2013 increased approximately 17 % to $ 46.0 million compared to $39.4 million reported in the same period in the prior year. Stelmi segment income was $6.9 million in the first quarter of 2013. Excluding Stelmi, segment income would have decreased slightly in the first quarter of 2013 to $39.1 million compared to $39.4 million reported in the same period in the prior year. This decrease is mainly due to lower sales to the prescription and consumer health care market offset by higher margins on product sales compared to the prior year.

FOOD + BEVERAGE SEGMENT

Operations that sell dispensing systems primarily to the food and beverage markets form the Food + Beverage segment.

Three Months Ended March 31,	2013			2012

Net Sales	$	85,292		$	75,304
Segment Income	8,550			6,788
Segment Income as a percentage of Net Sales	10.0		%	9.0		%

Net sales for the quarter ended March 31, 2013 increased approximately 13 % to $ 85.3 million compared to $75.3 million in the first quarter of the prior year. Foreign currency changes had no measureable impact on the total segment sales. Excluding foreign currency rate changes, sales to the food market increased 14% and sales to the beverage market increased approximately 13% in the first quarter of 2013 compared to the same period in the prior year. The majority of the food increase is driven by tooling sales, which increased $4.9 million over the first quarter of 2012 while the beverage increase is mainly due to increased product sales globally, especially in Asia for the functional bottled water market.

Segment income in the first quarter of 2013 increased approximately 26 % to $ 8.6 million compared to $6.8 million during the same period in the prior year. The strong growth in product sales noted above along with improved manufacturing productivity and cost absorption contributed to the improvements in the first quarter of 2013 compared to the same period in the prior year.

CORPORATE & OTHER

In addition to our three operating business segments, AptarGroup assigns certain costs to “Corporate & Other,” which is presented separately in Note 10 of the Notes to the Condensed Consolidated Financial Statements. Corporate & Other primarily includes certain corporate compensation and information system costs which are not allocated directly to our operating segments. Corporate & Other expense increased to $ 10.8 million for the quarter ended March 31, 2013 compared to $8.6 million in the first quarter of the prior year mainly due to increased costs associated with hedges in place to support our foreign currency cross border transactions and higher personnel costs.

FOREIGN CURRENCY

Table of Contents

exchange exposure is to the Euro, but we also have foreign exchange exposure to the Brazilian Real, British Pound, Swiss Franc and South American and Asian currencies, among others. We manage our exposures to foreign exchange principally with forward exchange contracts to hedge certain transactions and firm purchase and sales commitments denominated in foreign currencies. A strengthening U.S. dollar relative to foreign currencies has a dilutive translation effect on our financial statements. Conversely, a weakening U.S. dollar has an additive effect. In some cases, we sell products denominated in a currency different from the currency in which the related costs are incurred. Changes in exchange rates on such inter-country sales could materially impact our results of operations.

QUARTERLY TRENDS

Our results of operations in the last quarter of the year typically are negatively impacted by plant shutdowns in December. In the future, our results of operations in a quarterly period could be impacted by factors such as changes in product mix, changes in material costs, changes in growth rates in the industries to which our products are sold, recognition of equity based compensation expense for retirement eligible employees in the period of grant and changes in general economic conditions in any of the countries in which we do business.

We generally incur higher stock option expense in the first quarter compared with the rest of the fiscal year. Our estimated stock option expense on a pre-tax basis (in $ millions) for the year 2013 compared to 2012 is as follows:

	2013		2012
First Quarter	$	6.5	$	5.8
Second Quarter (estimated for 2013)	2.8		2.9
Third Quarter (estimated for 2013)	2.2		2.1
Fourth Quarter (estimated for 2013)	2.1		1.9
	$	13.6	$	12.7

LIQUIDITY AND CAPITAL RESOURCES

Our primary sources of liquidity are cash flow from operations and our revolving credit facility. In the first quarter of 2013, our operations provided approximately $26.1 million in cash flow compared to $13.7 million for the same period a year ago. In both periods, cash flow from operations was primarily derived from earnings before depreciation and amortization. During the first quarter of 2013, we utilized the majority of the operating cash flows to finance capital expenditures.

We used $32.7 million in cash for investing activities during the first quarter of 2013, compared to $42.0 million during the same period a year ago. The decrease in cash used for investing activities is due primarily to $7.7 million less spent on capital expenditures in the first quarter of 2013 compared to the first quarter of 2012. Cash outlays for capital expenditures for 2013 are estimated to be approximately $160 million but could vary due to changes in exchange rates as well as the timing of capital projects.

We received approximately $8.4 million in cash provided by financing activities in the first quarter of 2013 compared to using $32.4 million in the first quarter of the prior year. In the first quarter of 2012, we utilized $46 million of funds repatriated during the quarter to pay down a portion of our revolving credit facility. No funds were repatriated during the first quarter of 2013 which required us to increase borrowings on our revolving credit facility.

Cash and equivalents decreased to $225.1 million at March 31, 2013 from $229.8 million at December 31, 2012. Total short and long-term interest bearing debt increased in the first quarter of 2013 to $441.6 million from $427.5 million at December 31, 2012. The ratio of our Net Debt (interest bearing debt less cash and cash equivalents) to Net Capital (stockholder’s equity plus Net Debt) was 13.5% at the end of March 2013 compared to 12.5% at December 31, 2012.

Our U.S. operations generate sufficient cash flows to fund their liquidity needs and do not depend on cash located outside of the U.S. for their operations. Nevertheless, we are a dividend payer and have an active share repurchase program. These two items are funded with operating cash flows from the U.S. and are supplemented by additional borrowings from our revolving credit facility and the repatriations of current year foreign earnings. Specifically, in the U.S., we have an unsecured $300 million revolving line of credit of which $250 million was unused and available as of March 31, 2013 and believe we have the ability to borrow additional funds should the need arise. On January 31, 2013, we amended the revolving credit facility to, among other things, add a swingline loan sub-facility and extend the maturity date for the revolving credit facility by one year, to January 31, 2018. To take advantage of low interest rates during the past year, we completed a $125 million private placement on September 5, 2012, consisting of $75 million of 10 year notes at an interest rate of 3.25% and $50 million of 12 year notes at an interest rate of 3.40%.

Our revolving credit facility and certain long-term obligations require us to satisfy certain financial and other covenants including:

		Requirement		Level at March 31, 2013
Debt to total capital ratio		Maximum of 55%		24.1%

Based upon the above debt to total capital ratio covenant we had the ability to borrow approximately an additional $1.3 billion at March 31, 2013 before the 55% requirement would be exceeded.

Our foreign operations have historically met cash requirements with the use of internally generated cash or borrowings. These foreign subsidiaries have financing arrangements with several foreign banks to fund operations located outside the U.S., but all these lines are uncommitted. Cash generated by foreign operations has generally been reinvested locally. The majority of our $225.1 million in cash and equivalents is located outside of the U.S. We manage our global cash requirements considering (i) available funds among the many subsidiaries through which we conduct business, (ii) the geographic location of our liquidity needs, and (iii) the cost to access international cash balances. The repatriation of non-U.S. cash balances from

Table of Contents

certain subsidiaries could have adverse tax consequences as we may be required to pay and record income tax expense on these funds. Historically, the tax consequences associated with repatriating current year earnings to the U.S. has been between 10% and 14% of the repatriated amount. We would not expect future impacts to be materially different.

We believe we are in a strong financial position and have the financial resources to meet business requirements in the foreseeable future. We have historically used cash flow from operations as our primary source of liquidity. Our primary uses of liquidity are to invest in equipment and facilities that are necessary to support our growth and to make acquisitions that will contribute to the achievement of our strategic objectives. The acquisition of the Stelmi group was funded with cash available from our European operations. In the event that customer demand would decrease significantly for a prolonged period of time and negatively impact cash flow from operations, we would have the ability to restrict and significantly reduce capital expenditure levels, as well as evaluate our acquisition strategy and dividend and share repurchase programs. A prolonged and significant reduction in capital expenditure levels could increase future repairs and maintenance costs as well as have a negative impact on operating margins if we were unable to invest in new innovative products.

On April 11, 2013, the Board of Directors declared a quarterly dividend of $0.25 per share payable on May 17, 2013 to stockholders of record as of April 26, 2013.

OFF-BALANCE SHEET ARRANGEMENTS

We lease certain warehouse, plant and office facilities as well as certain equipment under noncancelable operating leases expiring at various dates through the year 2029. Most of the operating leases contain renewal options and certain equipment leases include options to purchase during or at the end of the lease term. Other than operating lease obligations, we do not have any off-balance sheet arrangements.

RECENTLY ISSUED ACCOUNTING STANDARDS

In July 2012, the FASB amended the guidance on the annual testing of indefinite-lived intangible assets (other than goodwill) for impairment. The amended guidance will allow companies to first assess qualitative factors to determine whether it is more-likely-than-not that an indefinite-lived intangible asset might be impaired and whether it is necessary to perform the quantitative impairment test required under current accounting standards. This guidance will be effective for the Company’s fiscal year ending December 31, 2013, with early adoption permitted. The Company does not believe that this new guidance will have a material impact on its consolidated financial statements.

In March 2013, the FASB issued guidance which permits an entity to release cumulative translation adjustments into net income when a reporting entity (parent) ceases to have a controlling financial interest in a subsidiary or group of assets that is a business within a foreign entity. Accordingly, the cumulative translation adjustment should be released into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided, or, if a controlling financial interest is no longer held. The guidance will be effective for the Company’s fiscal years beginning after December 15, 2013; however, early adoption is permitted.

Other accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our consolidated financial statements upon adoption.

OUTLOOK

Looking to the second quarter, we anticipate our Beauty + Home segment’s income to improve from the disappointing first quarter results. We are optimistic that our legacy Pharma business will see more normalized order levels in the U.S. generic allergy and European consumer health care markets in the second quarter. Also, Aptar Stelmi is expected to continue to perform well. Our Food + Beverage segment is expected to continue to grow this year compared to the prior year provided the global economies do not deteriorate.

Our second quarter earnings per share guidance does not include any impact from our EOO plan. Currently, we anticipate earnings per share for the second quarter to be in the range of $0.73 to $0.78 compared to $0.61 per share a year ago. Prior year reported earnings per share included a negative $0.05 per share related to costs associated with the Aptar Stelmi acquisition.

FORWARD-LOOKING STATEMENTS

Certain statements in Management’s Discussion and Analysis and other sections of this Form 10-Q are forward-looking and involve a number of risks and uncertainties, including certain statements set forth in the Liquidity and Capital Resources, Off Balance Sheet Arrangements, and Outlook sections of this Form 10-Q. Words such as “expects,” “anticipates,” “believes,” “estimates,” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment, including but not limited to:

·	economic, environmental and political conditions worldwide;
·	changes in customer and/or consumer spending levels;

Table of Contents

·	the cost of materials and other input costs (particularly resin, metal, anodization costs and transportation and energy costs);
·	the availability of raw materials and components (particularly from sole sourced suppliers) as well as the financial viability of these suppliers;
·	our ability to contain costs and improve productivity;
·	the timing and successful completion of our EOO plan;
·	our ability to increase prices;
·	significant fluctuations in foreign currency exchange rates;
·	changes in capital availability or cost, including interest rate fluctuations;
·	volatility of global credit markets;
·	changes in capital availability or cost, including interest rate fluctuations;
·	the timing and magnitude of capital expenditures;
·	our ability to identify potential new acquisitions and to successfully acquire and integrate such operations or products;
·	direct or indirect consequences of acts of war or terrorism;
·	cybersecurity threats that could impact our networks and reporting systems;
·	the impact of natural disasters and other weather-related occurrences;
·	changes or difficulties in complying with government regulation;
·	changing regulations or market conditions regarding environmental sustainability;
·	work stoppages due to labor disputes;
·	fiscal and monetary policy, including changes in worldwide tax rates;
·	competition, including technological advances;
·	our ability to protect and defend our intellectual property rights, as well as litigation involving intellectual property rights;
·	the outcome of any legal proceeding that has been or may be instituted against us and others;
·	our ability to meet future cash flow estimates to support our goodwill impairment testing;
·	the demand for existing and new products;
·	our ability to manage worldwide customer launches of complex technical products, in particular in developing markets;
·	the success of our customers’ products, particularly in the pharmaceutical industry;
·	difficulties in product development and uncertainties related to the timing or outcome of product development;
·	significant product liability claims; and
·	other risks associated with our operations.

Although we believe that our forward-looking statements are based on reasonable assumptions, there can be no assurance that actual results, performance or achievements will not differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Please refer to Item 1A (“Risk Factors”) of Part I included in the Company’s Annual Report on Form 10-K for additional risk factors affecting the Company.

Table of Contents

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

A significant number of our operations are located outside of the United States. Because of this, movements in exchange rates may have a significant impact on the translation of the financial condition and results of operations of our entities. Our primary foreign exchange exposure is to the Euro, but we also have foreign exchange exposure to the Brazilian Real, British Pound, Swiss Franc and South American and Asian currencies, among others. A strengthening U.S. dollar relative to foreign currencies has a dilutive translation effect on our financial condition and results of operations. Conversely, a weakening U.S. dollar has an additive effect.

Additionally, in some cases, we sell products denominated in a currency different from the currency in which the related costs are incurred. Any changes in exchange rates on such inter-country sales may impact our results of operations.

We manage our exposures to foreign exchange principally with forward exchange contracts to hedge certain firm purchase and sales commitments and intercompany cash transactions denominated in foreign currencies.

The table below provides information as of March 31, 2013 about our forward currency exchange contracts. The majority of the contracts expire before the end of the second quarter of 2013.

			Average	Min / Max
	Contract Amount		Contractual	Notional
Buy/Sell	(in thousands)		Exchange Rate	Volumes

Swiss Franc/Euro	$	36,514	0.8104	33,597-36,514
Euro/Brazilian Real	19,314		3.0264	19,314-21,311
Euro/U.S. Dollar	11,893		1.3014	10,301-14,277
Euro/Mexican Peso	8,114		18.4891	7,897-8,804
Czech Koruna/Euro	6,454		0.0390	6,454-6,660
British Pound/Euro	4,779		1.1582	1,844-4,779
Euro/Swiss Franc	3,699		1.2263	299-3,699
U.S. Dollar/Chinese Yuan	3,350		6.2452	3,350-4,710
Euro/Argentinian Peso	2,398		7.0300	0-2,398
Euro/Russian Rouble	1,689		45.3677	1,689-1,689
Euro/Chinese Yuan	1,244		8.3775	1,244-2,268
U.S. Dollar/Argentinian Peso	1,000		5.4030	300-1,000
Other	3,510
Total	$	103,958

As of March 31, 2013, we have recorded the fair value of foreign currency forward exchange contracts of $1.1 million in prepaid and other, $2.7 million in accounts payable and accrued liabilities and $0.9 million in deferred and other non-current liabilities in the balance sheet.

ITEM 4. CONTROLS AND PROCEDURES

DISCLOSURE CONTROLS AND PROCEDURES

The Company’s management has evaluated, with the participation of the chief executive officer and chief financial officer of the Company, the effectiveness of the Company’s disclosure controls and procedures (as that term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934) as of March 31, 2013. Based on that evaluation, the chief executive officer and chief financial officer have concluded that these controls and procedures were effective as of such date.

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

During the quarter ended March 31, 2013, the Company implemented an enterprise resource planning system at an entity located in Stratford, Connecticut. Consequently, the control environment has been modified at this location. Other than this item, no other changes in the Company’s internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Securities Exchange Act of 1934) occurred during the Company’s fiscal quarter ended March 31, 2013 that materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

Table of Contents

PART II - OTHER INFORMATION

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

RECENT SALES OF UNREGISTERED SECURITIES

The employees of AptarGroup S.A.S. and Aptar France S.A.S., our subsidiaries, are eligible to participate in the FCP Aptar Savings Plan (the “Plan”). All eligible participants are located outside of the United States. An independent agent purchases shares of our Common Stock available under the Plan for cash on the open market and we do not issue shares. We do not receive any proceeds from the purchase of shares of our Common Stock under the Plan. The agent under the Plan is Banque Nationale de Paris Paribas Fund Services. No underwriters are used under the Plan. All shares are sold in reliance upon the exemption from registration under the Securities Act of 1933 provided by Regulation S promulgated under that Act. During the quarter ended March 31, 2013, the Plan sold 4,957 shares of our Common Stock on behalf of the participants at an average price of $53.87 per share, for an aggregate amount of $267 thousand and did not purchase any shares of our Common Stock. At March 31, 2013, the Plan owns 29,931 shares of our Common Stock.

ISSUER PURCHASES OF EQUITY SECURITIES

The following table summarizes the Company’s purchases of its securities for the quarter ended March 31, 2013:


Period	Total Number Of Shares Purchased	Average Price Paid Per Share		Total Number Of Shares Purchased As Part Of Publicly Announced Plans Or Programs	Maximum Number Of Shares That May Yet Be Purchased Under The Plans Or Programs

1/1 – 1/31/13	--	$	--	--	1,973,691
2/1 – 2/28/13	108,000	52.83		108,000	1,865,691
3/1 – 3/31/13	93,000	54.43		93,000	1,772,691
Total	201,000	$	53.57	201,000	1,772,691

The Company announced the existing repurchase program on July 19, 2011. There is no expiration date for this repurchase program.

Table of Contents

ITEM 6. EXHIBITS

Exhibit 31.1	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Exhibit 31.2	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Exhibit 32.1	Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Exhibit 32.2	Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Exhibit 101	The following financial information from our Quarterly Report on Form 10-Q for the first quarter of fiscal 2013, filed with the SEC on May 6, 2013, formatted in Extensible Business Reporting Language (XBRL): (i) the Condensed Consolidated Statements of Income - Three Months Ended March 31, 2013 and 2012, (ii) the Condensed Consolidated Statements of Comprehensive Income – Three Months Ended March 31, 2013 and 2012, (iii) the Condensed Consolidated Balance Sheets - March 31, 2013 and December 31, 2012, (iv) the Condensed Consolidated Statements of Changes in Equity - Three Months Ended March 31, 2013 and 2012, (v) the Condensed Consolidated Statements of Cash Flows - Three Months Ended March 31, 2013 and 2012 and (vi) the Notes to Condensed Consolidated Financial Statements.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	AptarGroup, Inc.
	(Registrant)

	By /s/ ROBERT W. KUHN
	Robert W. Kuhn
	Executive Vice President,
	Chief Financial Officer and Secretary
	(Duly Authorized Officer and
	Principal Accounting and Financial Officer)


	Date: May 6, 2013

Table of Contents

INDEX OF EXHIBITS

Exhibit
Number	Description

31.1	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1	Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2	Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101	The following financial information from our Quarterly Report on Form 10-Q for the first quarter of fiscal 2013, filed with the SEC on May 6, 2013, formatted in Extensible Business Reporting Language (XBRL): (i) the Condensed Consolidated Statements of Income - Three Months Ended March 31, 2013 and 2012, (ii) the Condensed Consolidated Statements of Comprehensive Income – Three Months Ended March 31, 2013 and 2012, (iii) the Condensed Consolidated Balance Sheets - March 31, 2013 and December 31, 2012, (iv) the Condensed Consolidated Statements of Changes in Equity - Three Months Ended March 31, 2013 and 2012, (v) the Condensed Consolidated Statements of Cash Flows - Three Months Ended March 31, 2013 and 2012 and (vi) the Notes to Condensed Consolidated Financial Statements.

TABLE OF CONTENTS

Part I Financial Informationprint Item 1. Financial Statements (unaudited)print Note 1 Summary Of Significant Accounting Policiesprint Note 2 - Inventoriesprint Note 3 Goodwill and Other Intangible Assetsprint Note 4 Retirement and Deferred Compensation Plansprint Note 5 Accumulated Other Comprehensive Incomeprint Note 6 Derivative Instruments and Hedging Activitiesprint Note 7 Commitments and Contingenciesprint Note 8 Stock Repurchase Programprint Note 9 Earnings Per Shareprint Note 10 Segment Informationprint Note 11 Acquisitionsprint Note 12 Stock-based Compensationprint Note 13 Income Tax Uncertaintiesprint Note 14 Fair Valueprint Note 15 Restructuring Initiativeprint Item 2. Management S Discussion and Analysis Of Financial Condition and Results Of Operationsprint Item 3. Quantitative and Qualitative Disclosures About Market Riskprint Item 4. Controls and Proceduresprint Part II - Other Informationprint Item 2. Unregistered Sales Of Equity Securities and Use Of Proceedsprint Item 6. Exhibitsprint

DIRECTORS	AGE	BIO
Xing	56	Dr. Xing has served as Executive Chair of the Board of Directors of Mundipharma China since 2022. Mundipharma is a multinational pharmaceutical leader. From 2019 to 2022, Dr. Xing held the position of Global Senior Vice President, President of Greater China for Envista Holdings Corporation (a dental equipment and supplies company). Prior to that, Dr. Xing served in numerous leadership roles at Eli Lilly and Company (a global pharmaceutical company), including Senior Director, Global New Product Planning and Payer Marketing, Pricing, Reimbursement and Access of Lilly Diabetes from 2018 to 2019, Senior Director, Global Payer Marketing, Pricing, Reimbursement and Access of Lilly Diabetes from 2015 to 2018, Vice President of Lilly China Oncology from 2012 to 2014 and Vice President of Corporate and Government Affairs and Market Access from 2010 to 2012, while based in Shanghai. Prior to Eli Lilly, from 2007 to 2010 Dr. Xing was Vice President and General Manager of Asia Pacific and Japan Operations at Panomics and Affymetrix, which was acquired by Thermo Fisher Scientific. Dr. Xing was General Manager and China President of Illumina (a global next generation gene sequencer company) from 2005 to 2007. Dr. Xing has served as a Board advisor of Lee Kum Kee Group (privately-held global manufacturer of sauces and condiments), since February 2025. Dr. Xing also served as Board advisor to the Board of Directors of Mars, Incorporated (a global manufacturer of confectionery, pet food and provider of animal care services) from 2019 to 2024. Dr. Xing has a PhD in biology from the Hong Kong University of Science and Technology.
Wunderlich	58	Mr. Wunderlich has served as the President and CEO of Huhtamaki Oyj (a Nasdaq Helsinki-listed global food packaging company) since January 2025. Prior to this role, he was an independent consultant and a senior advisor to private equity firms. He is currently the Chair of the Board of Directors of Shepherd Building Group Ltd. (a privately held U.K. construction company). Until January 2025, Mr. Wunderlich served as a director of Huhtamaki Oyj, Essentra PLC (an LSE-listed manufacturer and distributor of essential industrial components) and Klöckner Pentaplast (a privately held international manufacturer of plastic packaging products for the pharma, healthcare and food industries headquartered in Luxembourg). He is a former member of Amcor Limited’s Global Executive Team and former President of the business group Amcor Flexibles Asia Pacific (packaging solutions including healthcare and pharma packaging). Mr. Wunderlich also formerly served as a director of LINPAC Group and AMVIG Group.
Trerotola	57	Mr. Trerotola has served as the Chief Executive Officer for Enovis Corporation since April 2022 and as President and Chief Executive Officer of its predecessor Colfax Corporation from July 2015 to April 2022. He has served as Chair of the board of directors of Enovis since May 2023. Enovis is an innovation-driven medical technology company formed when Colfax separated from its industrial businesses and was renamed. Prior to joining Enovis, from 2014 to 2015, Mr. Trerotola was an Executive Vice President and a member of the Office of the Chief Executive at DuPont de Nemours, Inc. (a global innovation leader with technology-based materials and solutions) and from 2013 to 2014 he served as Senior Vice President. While at DuPont, he was responsible for DuPont’s Electronics & Communications and Safety & Protection segments (2014), and he also had corporate responsibility for DuPont’s Asia-Pacific business. Prior to joining DuPont in 2013, Mr. Trerotola served in leadership roles at Danaher Corporation (a global science and technology innovator), since 2007, and was most recently Vice President and Group Executive for Life Sciences.
Tanda	65	Mr. Tanda became President and Chief Executive Officer of Aptar in February 2017. Prior to this, Mr. Tanda served from 2007 to 2017 as an Executive Managing Board Director at Royal DSM NV (leading global supplier of ingredients and material solutions for the food, dietary supplement, personal care, medical device, automotive, paint, electronic and bio-material markets), where he was responsible for DSM’s Nutrition and Pharma activities, as well as DSM’s presence in the Americas and various corporate duties. Mr. Tanda is a director of Ingredion Incorporated (a NYSE-listed global supplier of high-quality food and industrial ingredient solutions). Mr. Tanda was a director of Patheon NV (formerly a NYSE-listed company that provided pharmaceutical development and manufacturing services) from March 2016 until the company was sold to Thermo Fisher Scientific in August 2017.
Owens	70	B. CRAIG OWENS Age: 70 Independent Director since: 2018 Committees: Audit (Chair), Management Development and Compensation
Matthews	66	Ms. Matthews has been the Chair of Aptar’s Board since May 2023. Ms. Matthews is the former Chief Reputation Officer for Amway Corp. (a company that sells health, beauty and home care products), having served in that role from June 2020 to June 2021, responsible for overseeing Amway’s global reputation strategy and corporate social responsibility. Prior to those roles, Ms. Matthews spent six years as Regional President of the Americas at Amway, heading all operations in North, Central and South America. Prior to joining Amway in 2007 as Chief Marketing Officer, Ms. Matthews served in executive positions at established multinational beauty companies, served as President of the SoftSheen-Carson, Consumer Products Division of L’Oréal USA, held a leadership role at The Coca-Cola Company and an innovation role at CIBA Vision Corporation. She also worked for several other notable companies such as Bausch + Lomb, Procter & Gamble and General Mills. Ms. Matthews currently serves on the board of directors of Société BIC S.A. (a consumer product manufacturer) and Corewell Health Foundation (formerly Spectrum Health Foundation). Ms. Matthews is a former director of MillerKnoll, Inc. (formerly Herman Miller, Inc.) (a modern furniture design company), and Popeye’s Louisiana Kitchen Inc. (a U.S. restaurant chain).
Kampouri Monnas	69	GIOVANNA KAMPOURI MONNAS Age: 69 Independent Director since: 2010 Committees: Management Development and Compensation (Chair)
Glickman	30	Ms. Glickman has over 30 years of global financial and operational experience, including in the pharmaceutical industry, and is currently the Chief Financial Officer and Principal Accounting Officer of Criteo S.A., a global commerce media company, since September 2020. She previously held the position of Acting Chief Financial Officer at XPO, Inc., a leading global provider of transportation and logistics solutions, where she previously served as Senior Vice President, Corporate Finance and Transformation. She also held global executive roles at Novartis, Honeywell International and Bristol-Myers Squibb and started her career at PricewaterhouseCoopers. Since 2021, Ms. Glickman has served on the Board of Directors and is Chair of the Audit Committee for 2seventy bio, Inc., a biotech company (previously part of bluebird bio, Inc.) Ms. Glickman joined Aptar’s Board of Directors in 2023.
Fotiades	71	Mr. Fotiades was the Chairman of the Board of Aptar from May 2018 to May 2023. He has served as Executive Chairman of Elio Health, a private investment firm, since he co-founded the firm in 2022. Mr. Fotiades was the President and CEO of Cantel Medical Corp. (a NYSE-listed manufacturer of infection prevention and control products) from March 2019 until its acquisition by STERIS plc in June 2021. Mr. Fotiades was an Operating Partner in the healthcare practice of Five Arrows Capital Partners (Rothschild Merchant Banking) from April 2017 to March 2019. From 2007 to April 2017, he was a partner of Healthcare Investments at Diamond Castle Holdings LLC (private equity investing). Mr. Fotiades was chairman of Catalent Pharma Solutions, Inc., a provider of advanced technologies for pharmaceutical, biotechnology and consumer health companies, from June 2007 to February 2010. He is currently a director of Prologis, Inc. (a NYSE-listed integrated distribution facilities and services) and previously was a director of Cantel Medical Corp.


							Changes in
							Pension Value
							and
							Nonqualified
						Non ‐ Equity	Deferred
				Stock	Option	Incentive Plan	Compensation	All Other
		Salary	Bonus	Awards	Awards	Compensation	Earnings	Compensation	Total
Name and Principal Position	Year	($)	($)	($)	($)	($)	($)	($)	($)
Stephan B. Tanda	2024	1,175,000	—	5,938,995	1,631,049	765,209	353,814	63,390	9,927,457
President and	2023	1,118,500	168,000	4,974,288	1,166,652	769,829	658,184	59,676	8,915,129
Chief Executive Officer	2022	1,118,500	—	6,836,783	—	823,104	—	62,120	8,840,507
Robert W. Kuhn	2024	715,364	—	1,571,635	381,945	329,995	124,047	15,875	3,138,861
Executive Vice President	2023	681,299	72,000	1,448,503	302,401	332,150	394,194	16,136	3,246,683
and Chief Financial Officer	2022	671,174	—	1,905,883	—	349,858	—	26,313	2,953,228
Gael Touya	2024	601,971	—	1,132,170	281,671	330,140	226,737	879,903	3,452,592
President,	2023	573,294	54,184	1,010,498	220,224	380,421	935,699	765,822	3,940,142
Aptar Pharma	2022	561,328	—	1,130,815	—	503,939	—	1,089,827	3,285,909
Marc Prieur President, Aptar Beauty	2024	664,273	—	964,712	313,412	248,547	139,293	12,806	2,343,043
	2023	625,779	60,217	817,420	235,421	529,491	126,695	12,551	2,407,574
	2022	603,011	—	1,170,585	—	734,272	127,265	12,094	2,647,227
Hedi Tlili President, Aptar Closures	2024	575,571	—	1,028,964	269,299	534,080	389,093	52,087	2,849,094
Xiangwei Gong	2024	516,906	—	743,334	241,489	431,221	92,813	236,435	2,262,198
Executive Vice President, Strategic Group Development and President, Aptar Asia	2023	494,647	46,000	855,674	192,111	235,757	171,762	435,987	2,431,938
	2022	494,647	—	1,207,463	—	305,529	31,247	358,492	2,397,378

Customer name	Ticker
Colgate-Palmolive Company	CL
Performance Food Group Company	PFGC
Sysco Corporation	SYY
The Wendy's Company	WEN

Owner	Position	Direct Shares	Indirect Shares
Tanda Stephan B.	-	204,986	3,096
Tanda Stephan B.	-	156,078	2,436
Kuhn Robert	-	65,552	16,453
Touya Gael	-	33,906	0
Vinczeller Shiela	-	27,296	0
Ackerman Daniel	-	26,593	0
Vinczeller Shiela	-	20,467	0
Gong Xiangwei	-	17,859	404
Prieur Marc	-	13,828	0
Prieur Marc	-	13,764	0
Gong Xiangwei	-	12,974	482
Tlili Hedi	-	9,379	0
Tlili Hedi	-	8,986	0
Chainey Kimberly	-	8,619	0
Chainey Kimberly	-	7,848	0
Kampouri Monnas Giovanna	-	7,582	0
Matthews Candace S.	-	6,323	0
Kanu Vanessa	-	4,162	0
Montiel Maritza Gomez	-	4,024	0
FOTIADES GEORGE L	-	3,900	0
Glickman Sarah JS	-	894	0

ATR 10-Q Quarter ended March 31, 2013